Incyte Announces Positive Phase 1 Results for KRAS G12D Inhibitor and TGFβR2xPD1 Bispecific Antibody at ESMO 2025

Reuters

2025/10/13

Incyte Announces Positive Phase 1 Results for KRAS G12D Inhibitor and TGFβR2xPD1 Bispecific Antibody at ESMO 2025

Incyte Corporation has announced that results from Phase 1 proof-of-concept studies for two investigational compounds, INCA33890 and INCB161734, will be presented at the upcoming European Society of Medical Oncology (ESMO) Congress 2025 in Berlin. INCA33890 is a TGFβR2×PD-1-directed bispecific antibody being evaluated for advanced solid tumors, while INCB161734 is a novel, selective, and orally bioavailable KRAS G12D inhibitor under investigation for patients with advanced or metastatic solid tumors. The presentations are scheduled for October 17 and October 19, 2025, respectively, with additional data on the compounds in microsatellite stable colorectal cancer and pancreatic ductal adenocarcinoma to be discussed at an analyst and investor event during the congress. The results have not yet been presented and will be disclosed at the ESMO Congress.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Incyte Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20251012385380) on October 12, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2575844383"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2575844383\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2575844383?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-13 06:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2575844383","market":"nz","top_or_hot":-1,"title":"Incyte Announces Positive Phase 1 Results for KRAS G12D Inhibitor and TGFβR2xPD1 Bispecific Antibody at ESMO 2025","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Incyte Announces Positive Phase 1 Results for KRAS G12D Inhibitor and TGFβR2xPD1 Bispecific Antibody at ESMO 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Incyte Corporation has announced that results from Phase 1 proof-of-concept studies for two investigational compounds, INCA33890 and INCB161734, will be presented at the upcoming European Society of Medical Oncology (ESMO) Congress 2025 in Berlin. INCA33890 is a TGFβR2×PD-1-directed bispecific antibody being evaluated for advanced solid tumors, while INCB161734 is a novel, selective, and orally bioavailable KRAS G12D inhibitor under investigation for patients with advanced or metastatic solid tumors. The presentations are scheduled for October 17 and October 19, 2025, respectively, with additional data on the compounds in microsatellite stable colorectal cancer and pancreatic ductal adenocarcinoma to be discussed at an analyst and investor event during the congress. The results have not yet been presented and will be disclosed at the ESMO Congress.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Incyte Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20251012385380) on October 12, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Incyte Announces Positive Phase 1 Results for KRAS G12D Inhibitor and TGFβR2xPD1 Bispecific Antibody at ESMO 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIncyte Announces Positive Phase 1 Results for KRAS G12D Inhibitor and TGFβR2xPD1 Bispecific Antibody at ESMO 2025\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-13 06:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Incyte Announces Positive Phase 1 Results for KRAS G12D Inhibitor and TGFβR2xPD1 Bispecific Antibody at ESMO 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Incyte Corporation has announced that results from Phase 1 proof-of-concept studies for two investigational compounds, INCA33890 and INCB161734, will be presented at the upcoming European Society of Medical Oncology (ESMO) Congress 2025 in Berlin. INCA33890 is a TGFβR2×PD-1-directed bispecific antibody being evaluated for advanced solid tumors, while INCB161734 is a novel, selective, and orally bioavailable KRAS G12D inhibitor under investigation for patients with advanced or metastatic solid tumors. The presentations are scheduled for October 17 and October 19, 2025, respectively, with additional data on the compounds in microsatellite stable colorectal cancer and pancreatic ductal adenocarcinoma to be discussed at an analyst and investor event during the congress. The results have not yet been presented and will be disclosed at the ESMO Congress.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Incyte Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20251012385380) on October 12, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251012:nNDL1yqC1m:1","article_id":"2575844383","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2575844383","pubTimestamp":1760306724,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Incyte Corporation has announced that results from Phase 1 proof-of-concept studies for two investigational compounds, INCA33890 and INCB161734, will be presented at the upcoming European Society of Medical Oncology  Congress 2025 in Berlin. INCA33890 is a TGFβR2×PD-1-directed bispecific antibody being evaluated for advanced solid tumors, while INCB161734 is a novel, selective, and orally bioavailable KRAS G12D inhibitor under investigation for patients with advanced or metastatic solid tumors. The presentations are scheduled for October 17 and October 19, 2025, respectively, with additional data on the compounds in microsatellite stable colorectal cancer and pancreatic ductal adenocarcinoma to be discussed at an analyst and investor event during the congress. The results have not yet been presented and will be disclosed at the ESMO Congress.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate a","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","BK4139":"生物科技","BK4532":"文艺复兴科技持仓","BK4550":"红杉资本持仓","INCY":"因塞特医疗","BK4588":"碎股"},"translate_title":"Incyte在ESMO 2025上宣布KRAS G12D抑制剂和TGF β R2xPD1双特异性抗体的积极1期结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"INCY":0.9},"content_text":"Incyte Announces Positive Phase 1 Results for KRAS G12D Inhibitor and TGFβR2xPD1 Bispecific Antibody at ESMO 2025\n    \n\n        Incyte Corporation has announced that results from Phase 1 proof-of-concept studies for two investigational compounds, INCA33890 and INCB161734, will be presented at the upcoming European Society of Medical Oncology (ESMO) Congress 2025 in Berlin. INCA33890 is a TGFβR2×PD-1-directed bispecific antibody being evaluated for advanced solid tumors, while INCB161734 is a novel, selective, and orally bioavailable KRAS G12D inhibitor under investigation for patients with advanced or metastatic solid tumors. The presentations are scheduled for October 17 and October 19, 2025, respectively, with additional data on the compounds in microsatellite stable colorectal cancer and pancreatic ductal adenocarcinoma to be discussed at an analyst and investor event during the congress. The results have not yet been presented and will be disclosed at the ESMO Congress.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Incyte Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20251012385380) on October 12, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}